• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Skin patch delivers insulin in response to hyperglycemia [PreClinical]

byJudith KandelandJessica Lau
June 26, 2015
in Endocrinology, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Glucose-responsive vesicles (GRVs), nanoscale polymer spheres loaded with glucose oxidase (GOx) enzyme, released insulin cargo in response to hyperglycemic conditions in vitro.

2. In a mouse model of type 1 diabetes, GRVs were delivered transcutaneously via polymer microneedle (MN)-array patches and normalized blood glucose levels over several hours without risk of hypoglycemia.

Evidence Rating Level: 2 (Good)

Study Rundown: Diabetes, characterized by the inability of insulin to effectively break down glucose in the blood, affects hundreds of millions of people worldwide, with numbers increasing due to rising rates of obesity. Treatment usually involves painful needle pricks to measure blood glucose levels and insulin injections to treat hyperglycemia. An alternative therapeutic approach is a closed-loop system that can both monitor blood glucose concentrations and deliver insulin as needed.

Researchers in this study engineered GRVs, GOx and insulin molecules encapsulated in a biocompatible polymer shell that dissolves in oxygen-limited conditions. GOx was used as a sensor and trigger for insulin release because its enzymatic reaction with glucose consumes oxygen. Incubating GRVs in hyperglycemic conditions (HG) led to decreased oxygen concentrations. This was followed by a drastic reduction in GRV diameter and significantly higher insulin release as compared to incubation in normal glucose concentrations (NG), suggesting GRV disintegration. In a mouse model of type 1 diabetes, treatment with GRV-loaded MN-array patches resulted in prolonged lowered blood glucose levels as compared to treatment with MN-array patches containing free insulin. Serial administration of two lower-dose GRV-loaded patches was similarly effective without inducing hypoglycemia. In contrast, animals were at risk for hypoglycemia when treated with a GRV-loaded patch followed by an insulin-loaded patch.

Further studies on safety and effect duration are needed before GRV-loaded MN-array patches can be used clinically. Overall, this responsive insulin patch represents a biocompatible, noninvasive, and effective approach to glucose control which may in turn prevent more serious consequences of diabetes.

Click to read the study in PNAS

RELATED REPORTS

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

Relevant Reading: Materials for Diabetes Therapeutics

In-Depth [animal study]: GRVs shells that encapsulated GOx and insulin were composed of hyaluronic acid (HA), a molecule widely used for biological applications, linked to hydrophobic 2-nitroimidizole (NI). NI is reduced to hydrophilic 2-aminoimidazole under hypoxia, so GOx’s utilization of oxygen in the presence of glucose triggered GRV dissolution.

Oxygen concentration plummeted over the course of 10 minutes when GRVs were placed in HG (400 mg/dL glucose), with a smaller reduction in NG (100 mg/dL glucose). GRV average diameter decreased from 118 nm to ~4 nm after 24 hours in HG, implying dissolution and release of cargo. Further in vitro experiments showed that saturation of insulin release occurred after ~6 hours, and total insulin released reached approximately 250 µg/mL in HG as compared to under 100 µg/mL in NG (p<0.05 from 1-24 hours, n=3).

In animal experiments, GRVs were delivered transcutaneously using an HA-based 11×11 array of MNs measuring 36 mm2. In streptozotocin-induced type 1 diabetic mice, administering GRV-loaded MN-array patches at a 10 mg/kg insulin concentration lowered blood glucose levels from ~550 mg/dL to ~200 mg/dL for 4 hours, with levels remaining significantly lower than those in other treatment groups for 9 hours total (p<0.05, n=5). Importantly, administration of insulin-loaded patches had a shorter effect, with levels returning to baseline at 5 hours. Two GRV-loaded patches, each containing 5 mg/kg insulin, given one hour apart lowered glucose levels for 8 hours (p<0.05 compared to a single application, n=5); however, following the first GRV-loaded patch with an insulin-loaded patch further decreased glucose levels to borderline hypoglycemia. When given to healthy mice, insulin-loaded patches resulted in hypoglycemia risk while GRV-loaded patches did not change blood glucose levels.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetesinsulin
Previous Post

Ebola virus rapid diagnostic test kit shows promise in point-of-care testing

Next Post

Increased risk of stillbirth recurrence after a previous stillbirth

RelatedReports

Type 2 diabetes associated with reduction in disability-free life years
Chronic Disease

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

January 16, 2023
Pediatric DKA associated with recent acute care visits
Cardiology

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

January 11, 2023
Cardiology

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

December 26, 2022
Solitary kidney not associated with contrast-induced nephropathy
Chronic Disease

Dapagliflozin reduces the risk of hospitalization in patients with chronic kidney disease

December 26, 2022
Next Post
Increased risk of stillbirth recurrence after a previous stillbirth

Increased risk of stillbirth recurrence after a previous stillbirth

Annual CT safe and effective for screening of nonsolid lung nodules

Annual CT safe and effective for screening of nonsolid lung nodules

Amniotic fluid lactate associated with labor disorders

Amniotic fluid lactate associated with labor disorders

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options